Business

Biotech, pharma, and money in science

Biotech

Digital event: Combating Covid-19

By Matthew Herper

Gilead Covid
Business

Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know

By Andrew Joseph, Adam Feuerstein, Damian Garde, and Matthew Herper

Biotech

Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer

By Adam Feuerstein

Boston Scientific
Business

Boston Scientific cutting hours and pay as revenue drops

By Jonathan Saltzman — Boston Globe

Scorecard
Biotech

The biotech scorecard for the second quarter: 18 stock-moving events to watch

By Adam Feuerstein

Vascepa pill handout
Biotech

Amarin loses legal fight over heart drug patent; shares sink

By Adam Feuerstein

Casal Palocco hospital
Health

‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19

By Elizabeth Cooney

Artificial intelligence
Biotech

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

By Adam Feuerstein and Matthew Herper

Merck logo
Biotech

Drug makers grounding salespeople as coronavirus impact on business spreads

By Adam Feuerstein

Vaccine glass bottles
Biotech

How one company made $208 million on an untested coronavirus vaccine

By Damian Garde and Adam Feuerstein

Business

The Engine at MIT is revving up the potential of ‘tough tech’

By Scott Kirsner — Boston Globe

Thermo Fisher Scientific
Biotech

Thermo Fisher buys Dutch diagnostics company for $11.5 billion

By Jonathan Saltzman — Boston Globe

Daniel O'Day
Biotech

CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven

By Matthew Herper

Sangamo zinc fingers illo
Biotech

Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease

By Adam Feuerstein

Graph Vs Host Disease
Biotech

With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption

By Adam Feuerstein

Frank Reynolds, CEO of PixarBio, sentenced to 7 years for defrauding investors
Biotech

Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison

By Jonathan Saltzman — Boston Globe

Scale close up
Biotech

Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk

By Adam Feuerstein

Radiologists supervise MRI
Opinions Plus

Why medtech is a different beast than biotech in the life sciences pack

By Jonathan P. Gertler

ProstateCancerCell
Biotech

With new combination drug data, Exelixis takes another shot at prostate cancer treatment

By Adam Feuerstein

Daniel O'Day STAT Summit
Adam's Take

Investor impatience with Gilead reclamation project sparks acquisition chatter

By Adam Feuerstein

DNA Editing
Biotech

Beam Therapeutics raises $180 million in IPO

By Jonathan Saltzman — Boston Globe

Best Buy
Health Tech

Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so

By Erin Brodwin

Biotech

Biogen wins patent challenge to key multiple sclerosis drug

By Adam Feuerstein

Kenneth Frazier
Business

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

By Matthew Herper

Jorge Conde Andreessen Horowitz
Exclusive

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

By Erin Brodwin

Peanut allergy treatment
Biotech

FDA approves the first treatment for peanut allergy, but commercial success is hardly assured

By Adam Feuerstein

Biotech

European regulators could take a harder line on the review of an Agios blood cancer drug

By Adam Feuerstein

Adam's Take

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

By Adam Feuerstein

Hepatitis C virus model
Biotech

Spring Bank scraps hepatitis R&D after patient dies in trial

By Jonathan Saltzman — Boston Globe

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy